

# Table of contents

List of contributors, ix

Foreword to the second edition, xiv

Preface to the second edition, xvi

Acknowledgments, xvii

## PART 1 Influenza: Perspective

1 Human influenza: One health, one world, 3

*Daniel B. Jernigan and Nancy J. Cox*

2 Influenza pandemics: History and lessons learned, 20

*Arnold S. Monto and Robert G. Webster*

## PART 2 Structure and replication

3 Structure, disassembly, assembly, and budding of influenza viruses, 37

*Debiprosad Nayak, Sakar Shivakoti, Rilwan A. Balogun, Gwendolyn Lee, and Z. Hong Zhou*

4 The virus genome and its replication, 57

*Robert M. Krug and Ervin Fodor*

5 Influenza glycoproteins: Hemagglutinin and neuraminidase, 67

*Rupert J. Russell, Steven J. Gamblin, and John J. Skehel*

6 Proton channels of influenza A and B viruses, 101

*Chunlong Ma, Lawrence H. Pinto, and Robert A. Lamb*

7 The NS1 protein: A master regulator of host and viral functions, 114

*Robert M. Krug and Adolfo García-Sastre*

8 Structure and function of the influenza virus replication machinery and PB1-F2, 133

*Andrew Mehle and Jonathan A McCullers*

9 The genome and its manipulation: Recovery of the 1918 virus and vaccine virus generation,

146

*Gabriele Neumann and Yoshihiro Kawaoka*

10 Pathogenesis, 157

*Hans Dieter Klenk, Wolfgang Garten, and Mikhail Matrosovich*

## PART 3 Evolution and ecology of influenza viruses

11 Ecology and evolution of influenza viruses in wild and domestic birds, 175

*Ron A.M. Fouchier and Yi Guan*

12 Influenza in swine, 190

*Richard Webby and Juergen Richt*

13 Equine/Canine/Feline/Seal influenza, 203

*Thomas M. Chambers, Edward J. Dubovi, and Ruben O. Donis*

14 Emergence and Evolution of the 1918, 1957, 1968, and 2009 pandemic virus strains, 218

*Taia T. Wang and Peter Palese*

#### **PART 4 Epidemiology and surveillance**

15 Influenza surveillance and laboratory diagnosis, 231

*Maria Zambon*

16 Epidemiology of influenza, 250

*Marc-Alain Widdowson and Arnold S. Monto*

#### **PART 5 Immunology of influenza**

17 Innate immunity, 269

*Akiko Iwasaki and Malik Peiris*

18 Antibody-mediated immunity, 283

*Nicole Baumgarth, Michael C. Carroll, and Santiago Gonzalez*

19 Cell-mediated immunity, 298

*Stephen J. Turner, Peter C. Doherty, and Anne Kelso*

#### **PART 6 Vaccines and vaccine development**

20 Immunogenicity, efficacy of inactivated/live virus seasonal and pandemic vaccines, 313

*Wendy A. Keitel, Kathleen M. Neuzil, and John Treanor*

21 New approaches to vaccination, 327

*Chih-Jen Wei, Damian C. Ekiert, Gary J. Nabel, and Ian A. Wilson*

22 Control of influenza in animals, 337

*Ilaria Capua and Dennis J. Alexander*

23 Influenza vaccine production, 352

*Klaus Stöhr*

#### **PART 7 Clinical aspects and antivirals**

24 Human influenza: Pathogenesis, clinical features, and management, 373

*Frederick G. Hayden and Menno D. de Jong*

25 Antivirals: Targets and use, 392

*Michael G. Ison and Alan Hay*

26 The control of influenza and cost-effectiveness of interventions, 419

*Carolyn B. Bridges, Samuel K. Peasah, and Martin I. Meltzer*

27 Applications of quantitative modeling to influenza virus transmission dynamics, antigenic and genetic evolution, and molecular structure, 434

*Marc Lipsitch and Derek Smith*

28 Pandemic preparedness and response, 453

*Jonathan S. Nguyen-Van-Tam and Joseph Bresee*

29 Influenza: The future, 470

*Thomas J. Braciale*

## **PART 8 The outbreak of H7N9**

30 Appendix, 479

*Thomas J. Braciale*